CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Cetuximab/Gemcitabine +1 moredrug
Likely dose
Cetuximab once weekly, Gemcitabine twice weekly for six weeks, concurrent with daily radiotherapy for 28 daysAI-extracted
Key inclusion· 6
  • ✓Histologically confirmed pancreatic adenocarcinoma
  • ✓Clinical stage I, II, or III disease
  • ✓Radiographically measurable disease
  • ✓Tumor tissue available for EGFR status assessment by immunohistochemistry
Key exclusion· 7
  • ✕Active hepatitis or known HIV infection
  • ✕Active or uncontrolled infection
  • ✕Significant cardiac disease history
  • ✕Prior therapy targeting the EGF pathway

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00225784
NCT00225784Phase 2Completed
CompareCT.gov

A Phase II Trial of Cetuximab, Radiotherapy and Twice Weekly Gemcitabine in Patients With Adenocarcinoma of the Pancreas

Dartmouth-Hitchcock Medical Center·interventional·Posted Sep 26, 2005·Updated Jul 16, 2014

In Brief

A Phase 2 clinical trial evaluating Cetuximab/Gemcitabine and Radiotherapy for Pancreatic Cancer. Completed, enrolled 37 participants.

Detailed Summary

This study is designed to establish the safety and efficacy of a combination of Erbitux (cetuximab)/Gemzar (gemcitabine)/radiation in patients with pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 26, 2005
Enrollment StartFeb 1, 2005
Primary CompletionFeb 1, 2010
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 20.8 years ago

Interventions

Cetuximab/Gemcitabinedrug

Once weekly Cetuximab, twice weekly Gemcitabine for six weeks

Radiotherapyprocedure

Daily radiotherapy for 28 days